PE20211468A1 - Quimioterapia intraperitoneal mejorada con liposomas - Google Patents

Quimioterapia intraperitoneal mejorada con liposomas

Info

Publication number
PE20211468A1
PE20211468A1 PE2021000653A PE2021000653A PE20211468A1 PE 20211468 A1 PE20211468 A1 PE 20211468A1 PE 2021000653 A PE2021000653 A PE 2021000653A PE 2021000653 A PE2021000653 A PE 2021000653A PE 20211468 A1 PE20211468 A1 PE 20211468A1
Authority
PE
Peru
Prior art keywords
drug
liposome
enhanced
paclitaxel
taxane
Prior art date
Application number
PE2021000653A
Other languages
English (en)
Inventor
Michael G Oefelein
Natarajan Venkatesan
Nitin K Swarnakar
Teresa B Hong
Guru V Betageri
Ramachandran Thirucote
Lining Zhu Hutchinson
Original Assignee
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesorx Pharma Llc filed Critical Tesorx Pharma Llc
Publication of PE20211468A1 publication Critical patent/PE20211468A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion descrita en este documento esta dirigida una formulacion liposomal que comprende un farmaco quimioterapeutico, donde el farmaco quimioterapeutico es un farmaco taxano, y la formulacion liposomal comprende (a) el farmaco taxano, (b) dipalmitoil fosfatidilcolina (DMPC) y (c) dimirsitoil fosfatidil glicerol sodio (DMPG) en las relaciones 29 peso/peso de (a):(b):(c) de (1):(1,3 4,5):(0,4-2,5) y el farmaco taxano es paclitaxel, docetaxel, cabazitaxel, tesetaxel, DJ-927, TPI 287, larotaxel, ortataxel o DHA-paclitaxel. Dicha formulacion es util en el tratamiento de neoplasias tales como cancer de ovario o cancer peritoneal primario.
PE2021000653A 2018-11-02 2019-11-04 Quimioterapia intraperitoneal mejorada con liposomas PE20211468A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755026P 2018-11-02 2018-11-02
PCT/US2019/059655 WO2020093044A1 (en) 2018-11-02 2019-11-04 Liposomal enhanced intra-peritoneal chemotherapy

Publications (1)

Publication Number Publication Date
PE20211468A1 true PE20211468A1 (es) 2021-08-05

Family

ID=70462880

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000653A PE20211468A1 (es) 2018-11-02 2019-11-04 Quimioterapia intraperitoneal mejorada con liposomas

Country Status (16)

Country Link
US (1) US20220000777A1 (es)
EP (1) EP3873456A4 (es)
JP (1) JP2022506612A (es)
KR (1) KR20210113588A (es)
CN (1) CN113453667A (es)
AU (1) AU2019372441A1 (es)
BR (1) BR112021009940A8 (es)
CA (1) CA3118530A1 (es)
CL (1) CL2021001147A1 (es)
EA (1) EA202191228A1 (es)
IL (1) IL282860A (es)
MX (1) MX2021005110A (es)
PE (1) PE20211468A1 (es)
PH (1) PH12021551004A1 (es)
SG (1) SG11202104580PA (es)
WO (1) WO2020093044A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128173A (en) * 1975-10-28 1978-12-05 Harrison Lazarus Peritoneal fluid treatment apparatus, package and method
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
WO1996015774A1 (en) * 1994-11-18 1996-05-30 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
CA2524478A1 (en) * 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) * 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2009059449A1 (en) * 2007-11-05 2009-05-14 Celsion Corporation Novel thermosensitive liposomes containing therapeutic agents
CA2842306A1 (en) * 2011-07-19 2013-01-24 Stc.Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
CN104582732A (zh) * 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
US10010481B2 (en) * 2014-07-02 2018-07-03 Paolo Gobbi Frattini S.R.L. Flexible package with a sealed sterile chamber for the reconsitution and administration of fluid medicinal or nutritional substances instillable into the body of a patient
EP3256110A4 (en) * 2015-02-13 2018-11-21 Op Nano Co., Ltd. Compositions and methods of tumor treatment utilizing nanoparticles
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
AU2017205337B2 (en) * 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer

Also Published As

Publication number Publication date
SG11202104580PA (en) 2021-05-28
KR20210113588A (ko) 2021-09-16
US20220000777A1 (en) 2022-01-06
EP3873456A4 (en) 2022-07-27
CN113453667A (zh) 2021-09-28
CL2021001147A1 (es) 2021-11-26
CA3118530A1 (en) 2020-05-07
MX2021005110A (es) 2021-08-24
EA202191228A1 (ru) 2021-09-24
AU2019372441A1 (en) 2021-06-10
EP3873456A1 (en) 2021-09-08
BR112021009940A2 (pt) 2021-08-17
WO2020093044A1 (en) 2020-05-07
JP2022506612A (ja) 2022-01-17
IL282860A (en) 2021-06-30
PH12021551004A1 (en) 2021-10-04
BR112021009940A8 (pt) 2023-03-21

Similar Documents

Publication Publication Date Title
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
SV2018005742A (es) Inhibidores de mcl-1 macrocíclicos para tratar el cáncer
UY37870A (es) Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
PE20200733A1 (es) Inhibidores de kras g 12c y metodos para su uso
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
AR123996A2 (es) Compuestos tricíclicos novedosos como agentes antineoplásicos
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CL2022003046A1 (es) Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
BR112018076784A2 (pt) derivados de oxadiazol microbiocidas
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
BR112018013821A2 (pt) derivados de oxadiazol microbiocidas
BR112019002965A2 (pt) polietileno de peso molecular ultraelevado multi-modal de alto desempenho
AR099886A1 (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
CO2018007674A2 (es) Formulaciones para el tratamiento del cáncer de vejiga
CO2020000134A2 (es) Compuestos cetónicos bicíclicos y métodos de uso de los mismos
CL2020003339A1 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
CY1125348T1 (el) Νεοι ανταγωνιστες υποδοχεων β2 βραδυκινινης
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.